CBS CEO: Streaming “very important” to our future Last year CBS CEO Les Moonves was bullish about his company’s talks with Apple about a possible game-changer in TV.
“Apple TV is trying to change the universe a little bit,” he said last May.
“Apple is having conversations with everyone about doing their own streaming services,” he said last October.
But Moonves now says those talks have ceased, at least for the time being.
“We had conversations awhile back, and we haven’t had recent conversations with them,” Moonves told CNNMoney in an interview last week.
The prospect of a Netflix-like streaming TV service from Apple (AAPL, Tech30) is distinct from the existing Apple TV box, which connects big-screen TVs to a wide variety of services.
Best Recreation Companies To Invest In 2017: Nuance Communications Inc.(NUAN)
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers dictation and transcription solutions and services, which automate the input and management of medical information; and speech recognition solutions for radiology, cardiology, pathology, and related specialties that help healthcare providers dictate, edit, and sign reports without manual transcription. The company also offers mobile and consumer solutions and services comprising an integrated suite of voice control and text-to-speech solutions, desktop and portable computer dictation applications, predictive text technologies, mobile messaging services, and emerging services, such as dictation, Web search, and voicemail-to-text for manufacturers and suppliers of mobile phones, automotive products, personal navigation devices, computers, and other consumer electronics. In addition, it provides customer service business intelligence and authentication solutions for enterprises in the telecommunications, financial services, travel, entertainment, and government sectors to support, understand, and communicate with their customers. Further, the company offers document imaging, print management, and PDF solutions to multifunction printer manufacturers, home offices, small businesses, and enterprise customers; software development toolkits for independent software vendors; and licenses its software to multifunction printer manufacturers. Nuance Communications, Inc. markets and sells its products through direct sales force; its e-commerce Web site; and a network of resellers, including system integrators, independent software vendors, value-added resellers, hardware vendors, telecommunications carriers, and distributors. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in November 2005. Nuance Communications, Inc. was founded in 1992 and is headquartered in Burlington, Massachusetts. Advisors’ Opinion:
- [By Lee Jackson]
Nuance Communications Inc. (NASDAQ: NUAN) is the company that brought you the Siri application that you can talk to on your iPhone. The stock also got crushed after an earnings miss this year. Mega-investor Carl Icahn has accumulated a 16.9% share of the company and may be looking for more. The consensus target for the stock sits at $22.
- [By Monica Gerson]
Nuance Communications Inc. (NASDAQ: NUAN) is projected to post its quarterly earnings at $0.35 per share on revenue of $491.14 million.
Zebra Technologies Corp. (NASDAQ: ZBRA) is estimated to report its quarterly earnings at $1.22 per share on revenue of $878.67 million.
Best Recreation Companies To Invest In 2017: Regeneron Pharmaceuticals, Inc.(REGN)
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The companys trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipopro tein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi and Mitsubishi Tanabe Pharma Corporation; license and collaboration agreement with Bayer HealthCare; and Avalanche Biotechnologies, Inc., as well as Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The company was founded in 1988 and is headquartered in Tarrytown, New York.
- [By Ben Levisohn]
Regeneron Pharmaceuticals (REGN) has dropped 1.5% to $407.65 after getting cut to Market Perform from Outperform at Wells Fargo.
Boeing (BA) has fallen 2.2% to $129.80 after BofA Merrill Lynch cut the airline manufacturer to Underperform from Neutral.
Top Consumer Stocks For 2017: Portola Pharmaceuticals, Inc.(PTLA)
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The companys other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lees Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. Portola Pharmaceuticals, Inc. has a collaboration with Bristol-Myers Squibb and Pfizer Inc. to develop and commercialize apixaban, an oral anticoagulant. The company was founded in 2003 and is headquartered in South San Francisco, California.
- [By Lisa Levin]
Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.
Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.
- [By Lisa Levin]
Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.
Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.
Best Recreation Companies To Invest In 2017: Blackrock Global(BOE)
BlackRock Global Opportunities Equity Trust (the Trust), incorporated on February 22, 2005, is an investment trust. The Trusts primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions.
Under normal circumstances, the Trust invests its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives. BlackRock Advisors, LLC is an investment advisor of the Trust. The Trust invests in various sectors, such as energy, consumer p roducts, financial institutions, industrials, technology, basic materials, telecommunications, health care, real estate, transportation, aerospace and defense, automotive, building and development, and entertainment and leisure.
- [By Robert Rapier]
Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.
Best Recreation Companies To Invest In 2017: Kinross Gold Corporation(KGC)
Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, development, and production of gold properties. The companys gold production and exploration activities are carried out principally in Canada, the United States, the Russian Federation, Brazil, Chile, Ghana, and Mauritania. It also produces and sells silver. As of December 31, 2015, its proven and probable mineral reserves included 34.0 million ounces of gold, 41.0 million ounces of silver, and 1.4 billion pounds of copper. The company was founded in 1972 and is headquartered in Toronto, Canada.
- [By Wayne Duggan]
Citi also placed Neutral ratings on Goldcorp Inc. (USA) (NYSE: GG), Kinross Gold Corporation (USA) (NYSE: KGC) and Silver Standard Resources Inc. (USA) (NASDAQ: SSRI).
- [By Ben Levisohn]
Given revised commodity deck forecasts (particularly for Steel and Gold) and improved Balance Sheet health (Steels, Precious and Industrials Metals) we are upgrading our ratings on several stocks in our coverage. We generally favor companies that have already initiated specific self-help, have low-cost assets and are less exposed to China supply and demand dynamics. In Steels, we have increased our rating from Hold to Buy on Nucor (NUE) and from Sell to Hold on US Steel. We have also upgraded Kinross Gold (KGC) to a Hold on valuation…On higher-than-peer valuations, we reiterate Sell-rated Coeur Mining (CDE), Franco-Nevada (FNV), Goldcorp (GG), Teck Resources (TCK) and highly leveraged AK Steel given preference to issue further equity if possible.
- [By Monica Gerson]
Kinross Gold Corporation (USA) (NYSE: KGC) is projected to post a quarterly loss at $0.01 per share on revenue of $808.09 million.
Crocs, Inc. (NASDAQ: CROX) is expected to report its quarterly earnings at $0.05 per share on revenue of $265.90 million.